Is AbbVie (ABBV) a Buy Right Now?
A plain-English read on AbbVie stock — what the chart and the numbers are saying today, with no jargon and no hype.
What this means, in plain English
AbbVie is currently trading at $259.36. The stock is in an uptrend, meaning it is trading above its 200-day average of $223.83. This suggests that the long-term price direction has been positive. The 50-day average of $234.78 further confirms this upward movement over the last few months.
The RSI, or Relative Strength Index—a gauge of whether a stock has climbed too far, too fast—sits at 65.7. This level shows strength without being excessively overbought. With the price near its recent ceiling of $261.64, the data supports a buy decision for those watching the current momentum.
Should you buy AbbVie stock?
The data indicates a buy based on the current trend and support levels. While the price is near its 52-week high of $261.64, the consistent move above key averages suggests strength. Always consider your own risk tolerance before entering a position.
Is ABBV a good stock for beginners?
AbbVie is a large company, which can provide more stability than smaller, unproven businesses. However, the P/E ratio of 109.4—a measure of the price paid for each dollar of earnings—is quite high, which means you are paying a premium for these shares.
What's driving ABBV right now
The stock price is currently above its 200-day average of $223.83.
The P/E ratio of 109.4 suggests the stock is priced at a high multiple relative to its earnings.
The stock has established a recent support level, or floor, at $243.07.
The price is nearing its recent resistance level, or ceiling, of $261.64.
What AbbVie actually does
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie by the numbers
Wall Street consensus on ABBV is Buy. That is the analyst community's view, shown for context — it is not our read and not a recommendation.
AbbVie's earnings history
Earnings per share for AbbVie's last 4 reported financial years, as filed — EPS has fallen over that span. We don't hold analyst consensus estimates for these periods, so no beat-or-miss judgement is shown.
| Period end | EPS reported |
|---|---|
| 2025-12-31 | 2.37 |
| 2024-12-31 | 2.40 |
| 2023-12-31 | 2.73 |
| 2022-12-31 | 6.65 |
Who owns AbbVie?
Institutions — pension funds, asset managers, index providers — hold 76.9% of ABBV, and the concentration matters: the largest single holder alone controls 8.53% of the company.
| Holder | Shares | % held |
|---|---|---|
| 150.70M | 8.53% | |
| 114.88M | 6.50% | |
| 81.22M | 4.60% |
Names withheld — plus 3 more records not shown.
See who owns itWhat AbbVie insiders have been doing
Executives and directors must disclose their own trades in company stock. Of the last 6 disclosed transactions we hold for AbbVie, none were an open-market buy or sell — they are awards, vesting, option exercises or derivative conversions, which is normal and says nothing about conviction either way. Insiders sell for many ordinary reasons — scheduled plans, tax, diversification — so a sale is not by itself a signal.
| Insider | Date | Type | Shares | Value |
|---|---|---|---|---|
| 2026-05-08 | AWARD / VEST | 1.1K | — | |
| 2026-05-08 | AWARD / VEST | 1.1K | — | |
| 2026-05-08 | AWARD / VEST | 1.1K | — |
Names withheld — plus 3 more records not shown.
See which insidersThe numbers behind the read
Who in Washington has been trading ABBV?
Members of Congress must disclose trades over $1,000 within 45 days under the STOCK Act. At least 25 disclosures name ABBV — filed by 11 separate members or more and worth $53K–$445K combined (filings report bands, never exact amounts). 16 purchase-side, 9 sale-side, most recently on 2026-05-05.
| Member | Date | Action | Amount filed |
|---|---|---|---|
| 2026-05-05 | SELL | $1,001 - $15,000 | |
| 2026-05-05 | SELL | $1,001 - $15,000 | |
| 2025-12-18 | SELL | $1,001 - $15,000 |
Names withheld — plus 22 more records not shown.
See which membersWith the price holding above its 200-day average and showing steady momentum, the data points to a buy for this established company.
Don't guess. Practice this trade first.
Buy it with virtual cash and watch how it plays out — before a dollar of your own is on the line.
Practice ABBV risk-free in your paper portfolioPaper trading, the AI Read & live indicators are inside a Money GPS membership — one price, the whole platform.
Beginner questions about ABBV
Should I buy ABBV stock?+
Based on the current upward trend and the price sitting above its 200-day average, the data supports a buy.
Is ABBV a good long-term investment?+
The stock is currently trading above its 50-day average of $234.78 and 200-day average of $223.83, indicating a positive long-term trend.
Is ABBV a buy or a sell?+
The data indicates a buy, as the price is trending upward and holding above key support levels.
Is ABBV overvalued?+
With a P/E ratio of 109.4, investors are paying a high premium for the company's earnings compared to historical averages.
Is ABBV a good stock for beginners?+
It is a large company, but beginners should note the high P/E ratio of 109.4 and the price being near its 52-week high.
Important disclaimer
This page is for educational and informational purposes only and is not financial, investment, tax, or legal advice, nor a recommendation, offer, or solicitation to buy, sell, or hold AbbVie (ABBV) or any other security. The Money GPS is not a registered investment adviser, broker-dealer, or financial planner, and no content here should be relied upon to make an investment decision.
The verdict, indicators, and commentary are generated automatically — in part using AI — from third-party market data (via Yahoo Finance) that may be delayed, incomplete, or inaccurate, and is provided “as is” without any warranty. Figures reflect the market as of 2026-07-24 and change constantly; the read above may already be out of date. A “Buy,” “Hold,” or “Be Careful” label is a simplified, rules-based signal for beginners — not a price target or a guarantee of any outcome.
All investing involves risk, including the possible loss of your entire principal. Past performance and historical patterns do not guarantee future results. Always do your own research and consult a licensed financial professional who knows your personal circumstances before investing. You are solely responsible for your own investment decisions. The Money GPS and its authors may hold positions in the securities discussed and accept no liability for any loss arising from the use of this information.